Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma

NCT01478178 is registered in ClinicalTrials.gov with Kintara Therapeutics, Inc. as lead sponsor.

NCT NCT01478178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01478178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Lead sponsor
Kintara Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2011
Completion date
October 31, 2016
Enrollment
55 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, gbm, glioblastoma, glioblastoma multiforme, glioma